In the landscape of modern oncology, the treatment of high-risk biochemical recurrence (BCR) in prostate cancer has long been a source of clinical debate. For years, clinicians were forced to rely on androgen deprivation therapy (ADT) as a baseline, often waiting for the inevitable progression to metastatic disease before escalating treatment. However, the landmark international Phase III EMBARK trial (NCT02319837) has fundamentally shifted this paradigm.
In a recent expert-led discussion, Dr. Neal Shore, Medical Director of the Carolina Urologic Research Center, and Dr. Henry Woo, a prominent academic urological surgeon from Sydney, Australia, dissected the transformative findings of the EMBARK study. The results, which have led to regulatory approvals by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), offer a new, robust roadmap for managing patients with nonmetastatic castration-sensitive prostate cancer (nmCSPC) who are at high risk for metastasis.
Main Facts: The EMBARK Clinical Construct
The EMBARK trial was meticulously designed to address a critical gap in prostate cancer care: how to intervene effectively in patients who experience a rise in prostate-specific antigen (PSA) levels after initial definitive treatment, such as radical prostatectomy or radiation therapy, but have not yet developed visible metastatic disease.
The trial enrolled 1,068 patients across 244 sites in 17 countries, marking it as a truly global initiative. Participants were randomized in a 1:1:1 ratio into three distinct treatment arms:
- Combination Therapy: Enzalutamide plus leuprolide (an LHRH agonist).
- Monotherapy: Enzalutamide alone (an androgen receptor pathway inhibitor, or ARPI).
- Control Group: Placebo plus leuprolide (the then-standard of care).
A unique feature of the study design was the inclusion of a "treatment holiday." Treatment was suspended at week 37 for patients who achieved a PSA level of <0.2 ng/mL at week 36. Therapy was subsequently re-initiated if the PSA rose above specific thresholds (5.0 ng/mL for those without prior radical prostatectomy, or 2.0 ng/mL for those with prior surgery). This design was predicated on the belief that intermittent therapy could mitigate the chronic side effects of continuous hormonal suppression while maintaining efficacy in preventing metastasis.
Chronology of Discovery: From Design to Global Implementation
The journey of the EMBARK trial represents nearly a decade of rigorous scientific inquiry. Enrollment began in January 2015 and concluded in August 2018. As the trial progressed, the medical landscape evolved rapidly. The emergence of three major Phase III trials—SPARTAN, PROSPER, and ARAMIS—established that treatment intensification with an ARPI was superior in the setting of nonmetastatic castration-resistant prostate cancer (nmCRPC).
Reflecting these shifts, from February 2019 onward, EMBARK investigators implemented protocols to ensure that patients who showed PSA progression with a doubling time of ≤10 months were counseled on the availability of these newly validated therapies.
By 2023, the data matured sufficiently to take center stage as a plenary presentation at the American Urological Association (AUA) annual meeting. The subsequent publication of the findings in the New England Journal of Medicine and NEJM Evidence solidified the trial’s status as a practice-changing study. Today, these results underpin international clinical guidelines, providing clinicians with a clear mandate for early intervention in high-risk BCR patients.
Supporting Data: Efficacy and Quality of Life
The primary endpoint of the EMBARK trial was metastasis-free survival (MFS), a widely recognized and validated surrogate for overall survival in prostate cancer. After a median follow-up of 60.7 months, the results were definitive.
Metastasis-Free Survival (MFS)
- Combination Therapy: Patients receiving enzalutamide plus leuprolide saw a 5-year MFS rate of 87%, compared to 71% in the leuprolide-alone group. The hazard ratio (HR) of 0.42 indicated a 58% reduction in the risk of metastasis or death.
- Monotherapy: Enzalutamide monotherapy also demonstrated significant superiority, with an 80% MFS rate at 5 years. This represented a 37% reduction in the risk of metastasis or death compared to the leuprolide-only control group (HR 0.63).
Secondary Outcomes and Safety
Beyond MFS, both the combination and monotherapy arms significantly delayed PSA progression and the time to the initiation of subsequent antineoplastic therapies. While overall survival (OS) data remain immature, the trend is positive, with an HR for death of 0.59 in the combination arm.
Safety profiles were consistent with the known side-effect profiles of the drugs involved. While over 97% of participants reported an adverse event (AE) of some grade, the majority were mild to moderate.
- Combination Arm: Fatigue and hot flashes were the predominant side effects.
- Monotherapy Arm: Patients reported higher incidences of gynecomastia and breast tenderness but experienced fewer hot flashes than the leuprolide-treated groups.
Crucially, patient-reported outcomes (PROs) indicated that health-related quality of life was preserved across all arms. There were no clinically meaningful differences in functional status, as measured by the FACT-P total score, suggesting that patients could achieve superior cancer control without enduring a significant decline in their daily well-being.
Official Responses and Clinical Implications
The regulatory approval of enzalutamide for this indication is a testament to the trial’s success. However, Dr. Shore and Dr. Woo emphasize that the "one-size-fits-all" era of prostate cancer treatment is over.
Shared Decision-Making
The availability of both combination therapy and monotherapy allows for a more personalized approach. Clinicians are encouraged to engage in shared decision-making with patients, weighing the specific side-effect profiles (e.g., managing sexual function and libido vs. the risk of hot flashes or breast-related symptoms) against the desired level of therapeutic intensity.
The Role of Modern Imaging
One of the most significant caveats noted by the investigators is the rapid advancement of imaging technology. EMBARK utilized conventional imaging, whereas today’s standard frequently involves PSMA PET (Prostate-Specific Membrane Antigen Positron Emission Tomography). PSMA PET is significantly more sensitive at detecting micrometastatic disease. Consequently, while EMBARK provides the foundational evidence, future research must determine how to integrate PSMA PET results into the treatment algorithms for these high-risk BCR patients.
Future Research Directions
The investigators acknowledge several limitations. The current OS data are not yet definitive, and the study cohort was underrepresented by non-White populations, highlighting a need for greater diversity in future trials. Additionally, the long-term consequences of prolonged ARPI exposure and the nuances of serial intermittent therapy remain active areas of investigation.
Conclusion
The EMBARK trial stands as a monumental achievement in urological oncology. By demonstrating that enzalutamide—either in combination with ADT or as a monotherapy—significantly delays the progression to metastatic disease in high-risk patients, the study has provided physicians with a powerful new tool.
As Dr. Shore noted, the intellectual rigor required to navigate these clinical complexities is what keeps the medical community moving forward. With these results, the standard of care for high-risk biochemically recurrent prostate cancer has been successfully recalibrated, prioritizing both prolonged survival and the maintenance of patient quality of life. For clinicians, the mandate is clear: identify high-risk patients early, engage in nuanced discussions regarding treatment options, and leverage these new evidence-based strategies to improve patient outcomes.
For further reading and full reference details, the original article is available in the journal Future Oncology (doi: 10.1080/14796694.2025.2479331).
About the Author
